Interstitial Cystitis (IC)

Categories: Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Interstitial Cystitis

MalaCards integrated aliases for Interstitial Cystitis:

Name: Interstitial Cystitis 12 74 52 58 36 42 15 17 71 32
Painful Bladder Syndrome 52 58 71
Bladder Pain Syndrome 52 58 71
Interstitial Cystitis/painful Bladder Syndrome 52 58
Interstitial Cystitis/bladder Pain Syndrome 52 58
Trigonitis 52 71
Ic/bps 52 58
Ic/pbs 52 58
Chronic Interstitial Cystitis 71
Pelvic Congestion Syndrome 71
Cystitis, Interstitial 43
Pelvic Pain Syndrome 52
Ulcerative Cystitis 12
Pelvic Pain 42
Pbs 52
Ic 52


Orphanet epidemiological data:

interstitial cystitis
Prevalence: 1-5/10000 (Finland),1-5/10000 (United States),1-9/1000000 (Finland); Age of onset: All ages; Age of death: normal life expectancy;


External Ids:

Disease Ontology 12 DOID:13949
KEGG 36 H01551
MeSH 43 D018856
NCIt 49 C27189
ICD10 32 N30.1
MESH via Orphanet 44 D018856
ICD10 via Orphanet 33 N30.1
UMLS via Orphanet 72 C0282488 C0600040 C1720830 more
Orphanet 58 ORPHA37202
UMLS 71 C0152078 C0282488 C0600040 more

Summaries for Interstitial Cystitis

NIH Rare Diseases : 52 Interstitial cystitis (IC) is a chronic condition that causes painful urinary symptoms. Symptoms and severity can vary. Some people may have only mild discomfort, or feel tenderness or pressure in the bladder or pelvis. Others may experience intense bladder pain, urgent or frequent needs to urinate, or pain during sexual intercourse. Symptoms may be constant, or they may come and go. Some people with IC have Hunner's ulcers (areas of inflammation on the bladder wall, identified by cytoscopy ). The exact cause of IC is not known. While the symptoms are similar to those of a bladder infection, IC is not an infection. It occurs more commonly in women, and in people with other chronic pain disorders such as irritable bowel syndrome or fibromyalgia . There is no cure for IC, but there are treatment options to help relieve the symptoms. No single treatment works for all people with IC. Often, people try different treatments or combinations of treatments before finding something that works. Treatment options may include lifestyle changes , oral or topical medications, bladder instillations , neuromodulation therapy , Botox injections in the bladder muscles, and surgery (in rare cases). Without treatment, IC can affect a person's sleep, daily activities, and social life.

MalaCards based summary : Interstitial Cystitis, also known as painful bladder syndrome, is related to urethral syndrome and cholera, and has symptoms including pain and other symptoms associated with female genital organs, mittelschmerz and unspecified symptom associated with female genital organs. An important gene associated with Interstitial Cystitis is NGF (Nerve Growth Factor), and among its related pathways/superpathways are CREB Pathway and PAK Pathway. The drugs Cycloserine and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and kidney, and related phenotypes are pain and abnormality of the menstrual cycle

MedlinePlus : 42 Interstitial cystitis (IC) is a condition that causes discomfort or pain in the bladder and a need to urinate frequently and urgently. It is far more common in women than in men. The symptoms vary from person to person. Some people may have pain without urgency or frequency. Others have urgency and frequency without pain. Women's symptoms often get worse during their periods. They may also have pain with sexual intercourse. The cause of IC isn't known. There is no one test to tell if you have it. Doctors often run tests to rule out other possible causes of symptoms. There is no cure for IC, but treatments can help most people feel better. They include Distending, or inflating, the bladder Bathing the inside of the bladder with a drug solution Oral medicines Electrical nerve stimulation Physical therapy Lifestyle changes Bladder training In rare cases, surgery NIH: National Institute of Diabetes and Digestive and Kidney Diseases

KEGG : 36 Interstitial cystitis (IC), also referred to as bladder pain syndrome (BPS), is a chronic non-infectious inflammatory condition characterized by recurring discomfort, pain or pressure in the bladder and the surrounding pelvic region. IC/BPS most often affect females compared with males. The affected individuals experience urinary frequency and urgency. The duration of irritative symptoms associated with unpleasant sensation are longer than six weeks duration. At present, there are two major subtypes of IC/BPS: those with or without Hunner lesion, which are also known as ulcerative or non-ulcerative IC/BPS, respectively.

Wikipedia : 74 Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a type of chronic pain that... more...

Related Diseases for Interstitial Cystitis

Diseases in the Interstitial Cystitis family:

Chronic Interstitial Cystitis

Diseases related to Interstitial Cystitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1201)
# Related Disease Score Top Affiliating Genes
1 urethral syndrome 32.7 TAC1 P2RX3 NGF IL6 CXCL8
2 cholera 32.6 KNG1 IL6 EGF CXCL8
3 low compliance bladder 31.8 P2RX3 NGF
4 bacteriuria 30.9 UMOD IL6 CXCL8
5 acute cystitis 30.9 UPK3A UPK1A UMOD IL6 CXCL8
6 pyelonephritis 30.8 UMOD IL6 CXCL8
7 rhinitis 30.6 NGF KNG1 IL6 CXCL8
8 adenomyosis 30.6 NGF CXCL8 CDH1
9 keratoconjunctivitis 30.5 NGF IL6 CXCL8
10 vesicoureteral reflux 1 30.5 UPK3A UPK1A UMOD CXCL8
11 esophagitis 30.5 IL6 EGF CXCL8
12 hydronephrosis 30.4 UPK3A IL6 EGF CXCL8
13 myofascial pain syndrome 30.4 TRPV1 TAC1 KNG1
14 gastric ulcer 30.4 IL6 EGF CXCL8
15 keratitis, hereditary 30.4 NGF IL6 CXCL8
16 fibromyalgia 30.4 TACR1 SCN9A NGF IL6 CXCL8 BDNF
17 irritable bowel syndrome 30.4 TRPV1 TACR1 TAC1 NGF IL6 CXCL8
18 acute kidney failure 30.4 UMOD KNG1 EGF
19 radiculopathy 30.4 TAC1 IL6 CXCL8
20 neuroma 30.3 TRPV1 NGF IL6
21 adrenal gland pheochromocytoma 30.3 NGF BDNF
22 spinal cord injury 30.3 IL6 CXCL8 BDNF
23 peptic esophagitis 30.3 TRPV1 IL6 CXCL8
24 varicose veins 30.3 KNG1 IL6 CXCL8
25 urinary tract obstruction 30.3 UPK3A UMOD HBEGF EGF CDH1
26 anxiety 30.2 TAC1 NGF IL6 BDNF
27 duodenal ulcer 30.2 IL6 EGF CXCL8
28 aspiration pneumonia 30.1 TRPV1 TAC1 IL6
29 neurogenic bladder 30.1 UPK3A TRPV1 TACR1 TAC1 P2RX3 NGF
30 pheochromocytoma 30.0 NGF KNG1 IL6 EGF CDH1
31 mononeuropathy 30.0 TRPV1 TAC1 NGF
32 gastroenteritis 30.0 IL6 CXCL8 CDH1
33 neuritis 29.9 IL6 CXCL8 BDNF
34 corneal disease 29.9 NGF IL6 EGF CXCL8
35 brain edema 29.9 TJP1 KNG1 IL6
36 diabetic neuropathy 29.8 TRPV1 SCN9A NGF
37 pulmonary disease, chronic obstructive 29.8 TRPV1 TAC1 IL6 CXCL8
38 suppression of tumorigenicity 12 29.8 IL6 EGF CXCL8 CDH1
39 disease of mental health 29.8 TAC1 NGF IL6 BDNF
40 sleep apnea 29.8 TAC1 IL6 CXCL8 BDNF
41 complex regional pain syndrome 29.7 TACR1 TAC1 SCN9A IL6 CXCL8
42 sudden infant death syndrome 29.7 TACR1 IL6 CXCL8 BDNF
43 detrusor sphincter dyssynergia 29.7 TRPV1 TAC1 P2RX3 NGF
44 pyelitis 29.6 UPK3A UPK1A UMOD IL6 CXCL8
45 cerebral palsy 29.6 IL6 CXCL8 BDNF
46 dry eye syndrome 29.6 NGF IL6 EGF BDNF
47 pulpitis 29.6 TRPV1 TAC1 KNG1 IL6 CXCL8
48 sensory peripheral neuropathy 29.6 TRPV1 TAC1 NGF BDNF
49 macular retinal edema 29.6 TJP1 IL6 CXCL8
50 chronic cystitis 29.6 UPK3A UPK1A TRPV1 TAC1 P2RX3 NGF

Comorbidity relations with Interstitial Cystitis via Phenotypic Disease Network (PDN):

Acute Cystitis Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Interstitial Cystitis:

Diseases related to Interstitial Cystitis

Symptoms & Phenotypes for Interstitial Cystitis

Human phenotypes related to Interstitial Cystitis:

58 31 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0012531
2 abnormality of the menstrual cycle 58 31 hallmark (90%) Very frequent (99-80%) HP:0000140
3 abnormality of the urethra 58 31 hallmark (90%) Very frequent (99-80%) HP:0000795
4 urinary urgency 58 31 hallmark (90%) Very frequent (99-80%) HP:0000012
5 pollakisuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0100515
6 dyspareunia 58 31 hallmark (90%) Very frequent (99-80%) HP:0030016
7 nocturia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000017
8 abnormality of the labia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000058
9 urinary bladder inflammation 58 31 hallmark (90%) Very frequent (99-80%) HP:0100577
10 abnormal vagina morphology 31 occasional (7.5%) HP:0000142
11 abnormality of the bladder 58 Very frequent (99-80%)
12 abnormality of the genital system 58 Very frequent (99-80%)
13 abnormality of the vagina 58 Occasional (29-5%)
14 functional abnormality of the bladder 58 Very frequent (99-80%)

UMLS symptoms related to Interstitial Cystitis:

pain and other symptoms associated with female genital organs, mittelschmerz, unspecified symptom associated with female genital organs, other specified symptoms associated with female genital organs, female genital pain and other symptoms

MGI Mouse Phenotypes related to Interstitial Cystitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 CDH1 FZD8 HBEGF IL6 NGF P2RX3
2 growth/size/body region MP:0005378 10.03 BDNF CDH1 CKAP4 EGF HBEGF IL6
3 integument MP:0010771 9.97 BDNF CDH1 CKAP4 EGF HBEGF IL6
4 normal MP:0002873 9.61 BDNF CDH1 EGF FZD8 HBEGF NGF
5 renal/urinary system MP:0005367 9.23 FZD8 IL6 SCN9A TAC1 TJP1 TRPV1

Drugs & Therapeutics for Interstitial Cystitis

Drugs for Interstitial Cystitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 385)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cycloserine Approved Phase 4 68-41-7 401 6234
Nitric Oxide Approved Phase 4 10102-43-9 145068
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
Belladonna Approved, Experimental Phase 4
Desogestrel Approved Phase 4 54024-22-5 40973
Drospirenone Approved Phase 4 67392-87-4 68873
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
Tibolone Approved, Investigational Phase 4 5630-53-5
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
Danazol Approved Phase 4 17230-88-5 28417
Gemifloxacin Approved, Investigational Phase 4 175463-14-6 5464436 9571107
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
Azithromycin Approved Phase 4 83905-01-5 55185 447043
Misoprostol Approved Phase 4 59122-46-2 5282381
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Tranexamic Acid Approved Phase 4 1197-18-8 5526
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
Sodium citrate Approved, Investigational Phase 4 68-04-2
Norepinephrine Approved Phase 4 51-41-2 439260
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Gestodene Investigational Phase 4 60282-87-3 3033968
BCG vaccine Investigational Phase 4
Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
38 Antioxidants Phase 4
39 Renal Agents Phase 4
40 Anti-Infective Agents, Urinary Phase 4
41 Antimetabolites Phase 4
42 Vasodilator Agents Phase 4
43 Adrenergic alpha-2 Receptor Agonists Phase 4
44 Opiate Alkaloids Phase 4
s 1 (combination) Phase 4
46 diuretics Phase 4
47 Steroid Synthesis Inhibitors Phase 4
48 Fertility Agents Phase 4
49 Central Nervous System Stimulants Phase 4
50 Nicotinic Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 643)
# Name Status NCT ID Phase Drugs
1 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
2 Botulinum A Toxin Intravesical Injections Versus Bladder Overdistension in the Treatment of Patients With Painful Bladder Syndrome: A Prospective Randomized Study Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
3 Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain Unknown status NCT02213081 Phase 4 Ulipristal
4 Botox on Vulvar Vestibulitis Unknown status NCT00119886 Phase 4 Botulinum toxin
5 A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac Unknown status NCT01514175 Phase 4 IV Ibuprofen;IV Ketorolac
6 Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial. Unknown status NCT00844012 Phase 4 Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy);Cyclic OC (clormadinone acetate plus ethinil-estradiol)
7 Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis Unknown status NCT02237131 Phase 4 Oral contraceptives cyclic;Oral contraceptives continuous
8 Effectiveness of Self-cross-linked Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion Unknown status NCT02868437 Phase 4
9 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
10 The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4 Completed NCT02297100 Phase 4 Onabotulinumtoxin A
11 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
12 Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis Completed NCT01195116 Phase 4 Dexmedetomidine;Normal Saline
13 Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial Completed NCT00194610 Phase 4 Botox
14 To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain Completed NCT02000401 Phase 4 Ketorolac Tromethamine
15 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial) Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
16 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
17 Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients Completed NCT02534688 Phase 4 LNG-IUS;DMPA
18 Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis Completed NCT02427386 Phase 4 dynamized estrogen;placebo
19 Effect of Nicotine on Chronic Pelvic Pain Completed NCT00440505 Phase 4 Placebo;Nicotine (5 mg);Nicotine (10 mg)
20 Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis Completed NCT02480647 Phase 4 Levonorgestrel;Etonogestrel
21 Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial. Completed NCT01056042 Phase 4 intramuscular depot medroxyprogesterone acetate;ethinyl estradiol 30 micrograms, gestodene 75 micrograms
22 Efficacy of Paraspinous Anesthetic Block in Patients With Chronic Pelvic Pain Non-Responsive to Pharmacological Treatment Completed NCT01635205 Phase 4
23 The Impact of Local Estrogen on the Urogenital Microbiome in Genitourinary Syndrome of Menopause (GSM) Completed NCT03336437 Phase 4 Estradiol vaginal ring
24 Detection and Treatment Benefit of Microorganism (Chlamydia Trachomatis, Mycoplasma Hominis, Ureaplasma Urealyticum) in Overactive Bladder Patients Completed NCT00883818 Phase 4 azithromycin, doxycycline
25 The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial Completed NCT02475564 Phase 4 Placebo;Resveratrol
26 A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women Completed NCT00735852 Phase 4 Decapeptyl SR 11.25mg
27 Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide). Completed NCT01769781 Phase 4 anastrazole;GnRH analog alone
28 Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF Completed NCT01779232 Phase 4 Danazol;placebo
29 The Effect of Intracervical Lidocaine Injection Versus Topical Lidocaine Gel on the Pain Experienced by Patients Undergoing Tenaculum Application to the Cervix at the Time of an Office Gynecologic Procedure Completed NCT01421641 Phase 4 Intracervical Lidocaine Injection;Topical Lidocaine Gel
30 Which do You Think is the Best Treatment Choice in Primary Dysmenorrhea? Completed NCT03124524 Phase 4 estradiol valerate/dienogest;ethinylestradiol and drospirenone
31 A Novel Analgesic Method for Postoperative Pain Relief After Cesarean Section: Intraoperative Superior Hypogastric Block Completed NCT03897764 Phase 4
32 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
33 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial Completed NCT01262573 Phase 4
34 Randomized Clinical Trial Evaluating the Efficacy of Gentamicin/Azithromycin and Gemifloxacin/Azithromycin Combination Therapies as an Alternative Regimen for Uncomplicated Urogenital Gonorrhea Completed NCT00926796 Phase 4 Azithromycin;Gentamicin;Gemifloxacin
35 Medical Management of Late Intrauterine Death Using a Therapeutic Combination of Isosorbide Dinitrate and Oxytocin. Completed NCT02488642 Phase 4 Isosorbide Dinitrate;Misoprostol;Oxytocin
36 Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention Completed NCT00422708 Phase 4
37 Interstitial Cystitis: Examination of the Central Autonomic Network Recruiting NCT03008382 Phase 4 Metoprolol Tartrate Oral Tablet;Placebo Oral Tablet
38 Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain Recruiting NCT02214550 Phase 4 microgestin 1/20
39 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
40 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
41 A Randomized Controlled Trial (RCT) Comparing Presacral Nerve Block Versus Sham Block on Post-operative Pain in Women Undergoing Total Laparoscopic Hysterectomy. Recruiting NCT03646006 Phase 4 Bupivacaine;Placebo
42 The Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Fixation: A Randomized Trial Recruiting NCT03995641 Phase 4 marcaine and kenalog
43 A Randomized Clinical Trial Between Clindamycin Once and Thrice a Day in Septic Abortion. Recruiting NCT02309346 Phase 4 Clindamycin
44 The Effect of Antibiotics on Latency in Previable Prelabor Rupture of Membranes Between 18 0/7 and 22 6/7 Weeks Gestational Age Recruiting NCT04047849 Phase 4 Antibiotics, oral Azithromycin and oral Amoxicillin
45 A Prospective Cohort Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction Active, not recruiting NCT03199534 Phase 4 Botulinum toxin A 50u;Botulinum toxin A 100u;Botulinum toxin A 150u
46 Non-antimicrobial Alternative in Prophylaxis of Recurrent Urinary Tract Infections: a Prospective, Randomised-controlled, Double-blinded, Multicentre Study Not yet recruiting NCT04095572 Phase 4
47 Examining the Effects of Ketamine Treatment on Synaptic Plasticity in Depression Using PET Imaging Not yet recruiting NCT04091971 Phase 4 Ketamine
48 Safety and Efficacy of Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy; A Randomized Controlled Trial Not yet recruiting NCT03892668 Phase 4 Tranexamic Acid;oxytocin;placebo
49 Anterior And Multi-Compartment Vaginal Prolapse Repair Augmented With Decellularized Human Dermal Allograft: A Prospactive, Randomized Controlled, Post Market Study Not yet recruiting NCT03939715 Phase 4
50 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin

Search NIH Clinical Center for Interstitial Cystitis

Cochrane evidence based reviews: cystitis, interstitial

Genetic Tests for Interstitial Cystitis

Anatomical Context for Interstitial Cystitis

MalaCards organs/tissues related to Interstitial Cystitis:

Prostate, Testes, Kidney, Brain, Heart, T Cells, Endothelial

Publications for Interstitial Cystitis

Articles related to Interstitial Cystitis:

(show top 50) (show all 3229)
# Title Authors PMID Year
Targeting the SHIP1 Pathway Fails to Show Treatment Benefit in Interstitial Cystitis/Bladder Pain Syndrome: Lessons Learned from Evaluating Potentially Effective Therapies in This Enigmatic Syndrome. 61 42
31090511 2019
Interstitial cystitis: elements of diagnosis and place of histopathological examination. About 16 cases. 61 42
31131865 2018
Sciatic Nerve Variants in Patients Diagnosed With Sciatica: Is There a Correlation? 42
31738201 2019
Effect of Chinese herbal medicine on primary dysmenorrhea: A protocol for a systematic review and meta-analysis. 42
31567963 2019
Impact of ultrasound diagnosis for chronic pelvic pain. 42
31574844 2019
Editorial Comment. 42
31090510 2019
Histamine induces peripheral and central hypersensitivity to bladder distension via the histamine H1 receptor and TRPV1. 61
31790304 2020
Current and Future Directions of Stem Cell Therapy for Bladder Dysfunction. 61
31758372 2020
Urinary fungi associated with urinary symptom severity among women with interstitial cystitis/bladder pain syndrome (IC/BPS). 61
31028455 2020
Long noncoding RNA (MEG3) in urinal exosomes functions as a biomarker for the diagnosis of Hunner-type interstitial cystitis (HIC). 61
31595563 2020
Re: A Culture-Independent Analysis of the Microbiota of Female Interstitial Cystitis/Bladder Pain Syndrome Participants in the MAPP Research Network. 61
31721675 2020
Urinary microbiome in uncomplicated and interstitial cystitis: is there any similarity? 61
32006175 2020
Opioid prescription use in patients with interstitial cystitis. 61
31980841 2020
Voluntary exercise improves voiding function and bladder hyperalgesia in an animal model of stress-induced visceral hypersensitivity: A multidisciplinary approach to the study of urologic chronic pelvic pain syndrome research network study. 61
31944369 2020
Comparison of urodynamic results and quality of life between women with interstitial cystitis and overactive bladder. 61
32039798 2020
Concurrent urinary and bowel diversion: Surgical modification with sigmoid colon that avoids a bowel anastomosis. 61
31851467 2020
Self-perception of symptoms, medical help seeking, and self-help strategies of women with interstitial cystitis/painful bladder syndrome. 61
31970901 2020
Bioinformatics analysis of the Hub genes and key pathways of interstitial cystitis pathogenesis. 61
31663162 2020
Comparison of the Efficacy Between Transurethral Coagulation and Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients: A Prospective Randomized Controlled Trial. 61
31959549 2020
Painful interactions: Microbial compounds and visceral pain. 61
31634534 2020
BDNF promotes activation of astrocytes and microglia contributing to neuroinflammation and mechanical allodynia in cyclophosphamide-induced cystitis. 61
31931832 2020
The efficacy of pentosan polysulfate monotherapy for preventing recurrent urinary tract infections in women: A multicenter open-label randomized controlled trial. 61
31813658 2019
Serum sphingosine-1-phosphate levels in bladder pain syndrome/interstitial cystitis patients: could it help in diagnosis? 61
31792578 2019
Synergistic Effects of N-Acetylcysteine and Mesenchymal Stem Cell in a Lipopolysaccharide-Induced Interstitial Cystitis Rat Model. 61
31905757 2019
[Erratum to: Diagnosis and treatment of interstitial cystitis (IC/PBS). S2k guideline of the German Society of Urology]. 61
31776628 2019
Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome. 61
31844086 2019
Inhibition of urease activity in the urinary tract pathogens Staphylococcus saprophyticus and Proteus mirabilis by dimethylsulfoxide (DMSO). 61
31860153 2019
Utility of DNA Next-Generation Sequencing and Expanded Quantitative Urine Culture in Diagnosis and Management of Chronic or Persistent Lower Urinary Tract Symptoms. 61
31619534 2019
Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study. 61
31905280 2019
Evolution in technique of robotic intracorporeal continent catheterizable pouch after cystectomy. 61
31893282 2019
Critical evaluation of animal models of visceral pain for therapeutics development: A focus on irritable bowel syndrome. 61
31833625 2019
Small fiber polyneuropathy as a potential therapeutic target in interstitial cystitis/bladder pain syndrome. 61
31240362 2019
Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses. 61
30925127 2019
Serotonin exerts a direct modulatory role on bladder afferent firing in mice. 61
31520534 2019
Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. 61
31694837 2019
Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States. 61
31899034 2019
Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice. 61
31766439 2019
Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Possible Pathomechanisms and Practical Issues. 61
31689912 2019
A new look at the etiology of interstitial cystitis/bladder pain syndrome: extraordinary cultivations. 61
31363960 2019
Advanced Management of Patients With Ulcerative Interstitial Cystitis/Bladder Pain Syndrome. 61
31442473 2019
Potassium sensitivity test predicts hydrodistention efficacy in patients with bladder pain syndrome/interstitial cystitis. 61
31747364 2019
Clinical and morphological effects of hyperbaric oxygen therapy in patients with interstitial cystitis associated with fibromyalgia. 61
31690286 2019
[Diagnosis and treatment of interstitial cystitis (IC/PBS) : S2k guideline of the German Society of Urology]. 61
31659368 2019
To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis. 61
31193808 2019
Female lower urinary tract microbiota do not associate with IC/PBS symptoms: a case-controlled study. 61
30993388 2019
Improving clinical outcomes with lower motor voltage (≤3 V) during stage 1 sacral neuromodulation for interstitial cystitis or bladder pain syndrome. 61
31512775 2019
Differential expression of histamine receptors in the bladder wall tissues of patients with bladder pain syndrome/interstitial cystitis - significance in the responsiveness to antihistamine treatment and disease symptoms. 61
31718622 2019
Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome. 61
31752328 2019
Histological evidence supports low anesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome. 61
31254048 2019
Variations in bladder pain syndrome/interstitial cystitis (IC) definitions, pathogenesis, diagnostics and treatment: a systematic review and evaluation of national and international guidelines. 61
31073635 2019

Variations for Interstitial Cystitis

Expression for Interstitial Cystitis

Search GEO for disease gene expression data for Interstitial Cystitis.

Pathways for Interstitial Cystitis

Pathways related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
3 12.52 KNG1 IL6 FZD8 EGF CXCL8 CDH1
Show member pathways
Show member pathways
6 11.98 IL6 FZD8 EGF CDH1
Show member pathways
8 11.64 TJP1 IL6 CXCL8
9 11.64 TACR1 IL6 CXCL8 BDNF
10 11.62 NGF EGF BDNF
11 11.5 IL6 HBEGF CXCL8
12 11.47 IL6 EGF CXCL8
16 10.71 EGF BDNF
17 10.32 TACR1 TAC1

GO Terms for Interstitial Cystitis

Cellular components related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.92 TAC1 NGF KNG1 IL6 HBEGF EGF
2 extracellular region GO:0005576 9.85 TAC1 NGF KNG1 IL6 HBEGF EGF
3 axon GO:0030424 9.65 TAC1 SCN9A P2RX3 NGF BDNF
4 plasma membrane GO:0005886 9.5 UPK3A UPK1A UMOD TRPV1 TJP1 TACR1
5 apical plasma membrane urothelial plaque GO:0120001 8.96 UPK3A UPK1A

Biological processes related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 IL6 HBEGF EGF
2 modulation of chemical synaptic transmission GO:0050804 9.67 P2RX3 NGF BDNF
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.62 TRPV1 TACR1 TAC1 KNG1
4 sensory perception of pain GO:0019233 9.58 TRPV1 TAC1 SCN9A
5 positive regulation of acute inflammatory response GO:0002675 9.55 TAC1 IL6
6 nerve growth factor signaling pathway GO:0038180 9.52 NGF BDNF
7 negative regulation of heart rate GO:0010459 9.51 TRPV1 TAC1
8 regulation of protein localization to cell surface GO:2000008 9.48 EGF BDNF
9 positive regulation of collateral sprouting GO:0048672 9.46 NGF BDNF
10 tachykinin receptor signaling pathway GO:0007217 9.43 TACR1 TAC1
11 urinary bladder smooth muscle contraction GO:0014832 9.37 TRPV1 P2RX3
12 response to pain GO:0048265 9.33 TRPV1 TACR1 TAC1
13 detection of abiotic stimulus GO:0009582 9.26 TACR1 TAC1
14 inflammatory response GO:0006954 9.17 TRPV1 TACR1 TAC1 SCN9A KNG1 IL6
15 behavioral response to pain GO:0048266 9.13 TRPV1 SCN9A P2RX3

Molecular functions related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.02 NGF IL6 HBEGF EGF BDNF

Sources for Interstitial Cystitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....